CJC-1134-PC Injection

DRUG3 trials

Sponsors

ConjuChem, Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.

Conditions

Type 2 Diabetes Mellitus (T2DM)Type 2 Diabetes Mellitus - Poor Control

Phase 2

Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy

TerminatedNCT01514149

ConjuChemType 2 Diabetes Mellitus (T2DM)

Start: 2011-09-30End: 2013-03-31Updated: 2017-07-19

Phase 3

A Study of CJC-1134-PC Injection in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues

CompletedNCT07057271

Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.Type 2 Diabetes Mellitus - Poor Control

Start: 2021-05-27End: 2023-02-21Updated: 2025-07-09

A Study of CJC-1134-PC Injection in Antidiabetic Treatment-naive Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control

CompletedNCT07058545

Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.Type 2 Diabetes Mellitus - Poor Control

Start: 2021-04-16End: 2023-02-20Updated: 2025-07-10